<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01968694</url>
  </required_header>
  <id_info>
    <org_study_id>2010P002903</org_study_id>
    <nct_id>NCT01968694</nct_id>
  </id_info>
  <brief_title>Effects of Intravenous Lidocaine on Endometriosis Pain</brief_title>
  <official_title>Effects of Intravenous Lidocaine on Endometriosis Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are doing this research study to find out if intravenous (in your vein, &quot;IV&quot;) lidocaine
      can lessen pain from endometriosis. The U.S. Food and Drug Administration (FDA) has approved
      intravenous lidocaine to treat irregular heart beats, but the FDA has not approved
      intravenous lidocaine to treat pain from endometriosis. Intravenous lidocaine has been used
      for more than 25 years to treat different acute and chronic pain conditions but has not yet
      been studied for endometriosis pain.

      This is a cross-over trial over two months where one month you will receive the active
      medication (lidocaine) and one month you will receive the active placebo (diphenhydramine,
      commonly known as benadryl). We will compare the effect on pain from endometriosis of
      lidocaine to active placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Analogue Scale (VAS)</measure>
    <time_frame>15 minutes after start of infusion, 30 minutes after start of infusion, and 30 minutes after infusion complete from BL (pre-infusion)</time_frame>
    <description>Visual Analogue Scale (VAS) ranges from 0 (no pain) to 10 (the worse imaginable pain).
Change scores are calculated from baseline (pre-infusion) at 15 minutes after start of infusion, 30 minutes after start of infusion, and 30 minutes after infusion complete:
(15 minutes after start of infusion value - BL pre-infusion value) (30 minutes after start of infusion value - BL pre-infusion value) (30 minutes after infusion complete value - BL pre-infusion value)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form McGill Pain Questionnaire 2</measure>
    <time_frame>30 minutes, 1 week, and 1 month post-treatment from BL (pre-infusion)</time_frame>
    <description>Short-form McGill Pain Questionnaire version 2 consists of 22 pain items (Throbbing, Shooting, Stabbing, Sharp, Cramping, Gnawing, Hot-burning, Aching, Heavy, Tender, Splitting, Tiring-exhausting, Sickening, Fearful, Punishing-cruel, Electric-shock, Cold-freezing, Piercing, Pain caused by light touch, Itching, Tingling or 'pins and needles', and Numbness). Each item is rated on a scale from 0-10, where 0=none, and 10=worst possible pain. The total pain score is the sum of these 22 items, ranging from 0-220.
Change scores are calculated from baseline (pre-infusion) at 30 minutes, 1 week, and 1 month post-treatment:
(30 minutes post-treatment value - BL pre-infusion value)
(1 week post-treatment value - BL pre-infusion value)
(1 month post-treatment value - BL pre-infusion value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brief Pain Inventory (BPI): Pain on Average</measure>
    <time_frame>1 day, 1 week, and 1 month post-treatment from BL (pre-infusion)</time_frame>
    <description>The Pain on Average score in the Brief Pain Inventory is rated from 0-10, where 0 is no pain, and 10 is pain as bad as you can imagine.
Change scores are calculated from baseline (pre-infusion) at 1 day, 1 week, and 1 month post-treatment:
(1 day post-treatment value - BL pre-infusion value)
(1 week post-treatment value - BL pre-infusion value)
(1 month post-treatment value - BL pre-infusion value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>1 day, 1 week, and 1 month post-treatment from BL (pre-infusion)</time_frame>
    <description>The Hospital Anxiety and Depression Scale (HADS) consists of 14 items rated from 0-3 and 2 subscales Depression (7 items) and Anxiety (7 items). A higher score on each item represents more of each symptom (i.e., more depression or more anxiety). Each subscale score is the sum of the 7 items from each subscale.
A score of 0-7 = Normal, 8-10=Borderline abnormal (borderline case), and 11-21=Abnormal (case).
Change scores are calculated from baseline (pre-infusion) at 1 day, 1 week, and 1 month post-treatment:
(1 day post-treatment value - BL pre-infusion value)
(1 week post-treatment value - BL pre-infusion value)
(1 month post-treatment value - BL pre-infusion value)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>IV Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV diphenhydramine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Lidocaine</intervention_name>
    <arm_group_label>IV Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV diphenhydramine</intervention_name>
    <arm_group_label>IV diphenhydramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Reproductive age women ages 18 - 50

          -  Endometriosis diagnosed laparoscopically or by primary care physician or gynecologist
             using clinical criteria

          -  Pain for &gt; 6 months

          -  Pain most intense around time of menstrual cycle. Pain at least 5 on a 0-10 scale.

          -  Receiving regular monthly menses (cannot be receiving Depo-provera injections)

        Exclusion criteria:

          -  Pregnant or breastfeeding

          -  On lupron therapy

          -  History of myocardial infarction or cardiac arrhythmias including
             Wolff-Parkinson-White, severe sinoatrial, atrioventricular or intraventricular heart
             block in the absence of a pacemaker

          -  History of seizure disorder

          -  Significant anxiety, psychosis or other cognitive disorder limiting completion of
             study procedures

          -  History of alcohol or substance abuse

          -  Chronic pain symptoms other than chronic pelvic pain (excluding migraine pain)

          -  Known hypersensitivity to amide type anesthetics

          -  Known hypersensitivity to diphenhydramine (benadryl)

          -  History of treatment with lidocaine or mexiletene

          -  Having or showing signs and symptoms of liver disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antje Barreveld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital, Newton-Wellesley Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Pain Management Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2013</study_first_submitted>
  <study_first_submitted_qc>October 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2013</study_first_posted>
  <results_first_submitted>May 11, 2017</results_first_submitted>
  <results_first_submitted_qc>May 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2017</results_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Antje Barreveld, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>chronic pain</keyword>
  <keyword>intravenous lidocaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Only 19 of the 20 enrolled started the study because one participant did not participate past consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IV Lidocaine Then IV Diphenhydramine</title>
          <description>IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes.
IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes.</description>
        </group>
        <group group_id="P2">
          <title>IV Diphenhydramine Then IV Lidocaine</title>
          <description>IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes.
IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Visit 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (1 Month)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Visit 2 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IV Lidocaine Then IV Diphenhydramine</title>
          <description>IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes.
IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes.</description>
        </group>
        <group group_id="B2">
          <title>IV Diphenhydramine Then IV Lidocaine</title>
          <description>IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes.
IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visual Analogue Scale (VAS)</title>
        <description>Visual Analogue Scale (VAS) ranges from 0 (no pain) to 10 (the worse imaginable pain).
Change scores are calculated from baseline (pre-infusion) at 15 minutes after start of infusion, 30 minutes after start of infusion, and 30 minutes after infusion complete:
(15 minutes after start of infusion value - BL pre-infusion value) (30 minutes after start of infusion value - BL pre-infusion value) (30 minutes after infusion complete value - BL pre-infusion value)</description>
        <time_frame>15 minutes after start of infusion, 30 minutes after start of infusion, and 30 minutes after infusion complete from BL (pre-infusion)</time_frame>
        <population>2 participants in the IV Lidocaine arm are missing VAS 30 minutes after infusion started.
3 participants in the IV Lidocaine arm are missing VAS 30 minutes after infusion complete.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Lidocaine</title>
            <description>IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes</description>
          </group>
          <group group_id="O2">
            <title>IV Diphenhydramine</title>
            <description>IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visual Analogue Scale (VAS)</title>
          <description>Visual Analogue Scale (VAS) ranges from 0 (no pain) to 10 (the worse imaginable pain).
Change scores are calculated from baseline (pre-infusion) at 15 minutes after start of infusion, 30 minutes after start of infusion, and 30 minutes after infusion complete:
(15 minutes after start of infusion value - BL pre-infusion value) (30 minutes after start of infusion value - BL pre-infusion value) (30 minutes after infusion complete value - BL pre-infusion value)</description>
          <population>2 participants in the IV Lidocaine arm are missing VAS 30 minutes after infusion started.
3 participants in the IV Lidocaine arm are missing VAS 30 minutes after infusion complete.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes after start of infusion change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-4.5" upper_limit="-0.8"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-1.0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes after start of infusion change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-5.0" upper_limit="-2.3"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-2.7" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes after infusion complete change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-4.6" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-1.7" lower_limit="-2.7" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Short Form McGill Pain Questionnaire 2</title>
        <description>Short-form McGill Pain Questionnaire version 2 consists of 22 pain items (Throbbing, Shooting, Stabbing, Sharp, Cramping, Gnawing, Hot-burning, Aching, Heavy, Tender, Splitting, Tiring-exhausting, Sickening, Fearful, Punishing-cruel, Electric-shock, Cold-freezing, Piercing, Pain caused by light touch, Itching, Tingling or 'pins and needles', and Numbness). Each item is rated on a scale from 0-10, where 0=none, and 10=worst possible pain. The total pain score is the sum of these 22 items, ranging from 0-220.
Change scores are calculated from baseline (pre-infusion) at 30 minutes, 1 week, and 1 month post-treatment:
(30 minutes post-treatment value - BL pre-infusion value)
(1 week post-treatment value - BL pre-infusion value)
(1 month post-treatment value - BL pre-infusion value)</description>
        <time_frame>30 minutes, 1 week, and 1 month post-treatment from BL (pre-infusion)</time_frame>
        <population>participant in the IV diphenhydramine arm is missing SFMPQ total score 1 week post-treatment.
participants in the IV diphenhydramine arm are missing SFMPQ total score 1 month post-treatment.
participants in the IV Lidocaine arm are missing SFMPQ total score 1 month post-treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Lidocaine</title>
            <description>IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes</description>
          </group>
          <group group_id="O2">
            <title>IV Diphenhydramine</title>
            <description>IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Short Form McGill Pain Questionnaire 2</title>
          <description>Short-form McGill Pain Questionnaire version 2 consists of 22 pain items (Throbbing, Shooting, Stabbing, Sharp, Cramping, Gnawing, Hot-burning, Aching, Heavy, Tender, Splitting, Tiring-exhausting, Sickening, Fearful, Punishing-cruel, Electric-shock, Cold-freezing, Piercing, Pain caused by light touch, Itching, Tingling or 'pins and needles', and Numbness). Each item is rated on a scale from 0-10, where 0=none, and 10=worst possible pain. The total pain score is the sum of these 22 items, ranging from 0-220.
Change scores are calculated from baseline (pre-infusion) at 30 minutes, 1 week, and 1 month post-treatment:
(30 minutes post-treatment value - BL pre-infusion value)
(1 week post-treatment value - BL pre-infusion value)
(1 month post-treatment value - BL pre-infusion value)</description>
          <population>participant in the IV diphenhydramine arm is missing SFMPQ total score 1 week post-treatment.
participants in the IV diphenhydramine arm are missing SFMPQ total score 1 month post-treatment.
participants in the IV Lidocaine arm are missing SFMPQ total score 1 month post-treatment.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 minutes change from BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" lower_limit="-46" upper_limit="-8"/>
                    <measurement group_id="O2" value="-15" lower_limit="-30" upper_limit="-4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 week change from BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18" lower_limit="-43" upper_limit="-4"/>
                    <measurement group_id="O2" value="-17" lower_limit="-30" upper_limit="-6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month change from BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-35" upper_limit="24"/>
                    <measurement group_id="O2" value="-18" lower_limit="-26" upper_limit="-11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brief Pain Inventory (BPI): Pain on Average</title>
        <description>The Pain on Average score in the Brief Pain Inventory is rated from 0-10, where 0 is no pain, and 10 is pain as bad as you can imagine.
Change scores are calculated from baseline (pre-infusion) at 1 day, 1 week, and 1 month post-treatment:
(1 day post-treatment value - BL pre-infusion value)
(1 week post-treatment value - BL pre-infusion value)
(1 month post-treatment value - BL pre-infusion value)</description>
        <time_frame>1 day, 1 week, and 1 month post-treatment from BL (pre-infusion)</time_frame>
        <population>In the IV diphenhydramine arm 1 pt is missing BPI avg pain score at 1 week, and 2 are missing scores at 1 month. In the IV Lidocaine arm 1 pt is missing a score at 1 day, 1 is missing a score at 1 week, and 4 are missing scores at 1 month.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Lidocaine</title>
            <description>IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes</description>
          </group>
          <group group_id="O2">
            <title>IV Diphenhydramine</title>
            <description>IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brief Pain Inventory (BPI): Pain on Average</title>
          <description>The Pain on Average score in the Brief Pain Inventory is rated from 0-10, where 0 is no pain, and 10 is pain as bad as you can imagine.
Change scores are calculated from baseline (pre-infusion) at 1 day, 1 week, and 1 month post-treatment:
(1 day post-treatment value - BL pre-infusion value)
(1 week post-treatment value - BL pre-infusion value)
(1 month post-treatment value - BL pre-infusion value)</description>
          <population>In the IV diphenhydramine arm 1 pt is missing BPI avg pain score at 1 week, and 2 are missing scores at 1 month. In the IV Lidocaine arm 1 pt is missing a score at 1 day, 1 is missing a score at 1 week, and 4 are missing scores at 1 month.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 day change from BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-3" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-2" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 week change from BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-2" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-1" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month change from BL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-2" upper_limit="0"/>
                    <measurement group_id="O2" value="-1" lower_limit="-1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hospital Anxiety and Depression Scale (HADS)</title>
        <description>The Hospital Anxiety and Depression Scale (HADS) consists of 14 items rated from 0-3 and 2 subscales Depression (7 items) and Anxiety (7 items). A higher score on each item represents more of each symptom (i.e., more depression or more anxiety). Each subscale score is the sum of the 7 items from each subscale.
A score of 0-7 = Normal, 8-10=Borderline abnormal (borderline case), and 11-21=Abnormal (case).
Change scores are calculated from baseline (pre-infusion) at 1 day, 1 week, and 1 month post-treatment:
(1 day post-treatment value - BL pre-infusion value)
(1 week post-treatment value - BL pre-infusion value)
(1 month post-treatment value - BL pre-infusion value)</description>
        <time_frame>1 day, 1 week, and 1 month post-treatment from BL (pre-infusion)</time_frame>
        <population>In the IV diphenhydramine arm 1 pt is missing HADS scores at 1 week, and 3 pts are missing scores at 1 month. In the IV Lidocaine arm 3 pts are missing HADS scores at 1 month.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Lidocaine</title>
            <description>IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes</description>
          </group>
          <group group_id="O2">
            <title>IV Diphenhydramine</title>
            <description>IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hospital Anxiety and Depression Scale (HADS)</title>
          <description>The Hospital Anxiety and Depression Scale (HADS) consists of 14 items rated from 0-3 and 2 subscales Depression (7 items) and Anxiety (7 items). A higher score on each item represents more of each symptom (i.e., more depression or more anxiety). Each subscale score is the sum of the 7 items from each subscale.
A score of 0-7 = Normal, 8-10=Borderline abnormal (borderline case), and 11-21=Abnormal (case).
Change scores are calculated from baseline (pre-infusion) at 1 day, 1 week, and 1 month post-treatment:
(1 day post-treatment value - BL pre-infusion value)
(1 week post-treatment value - BL pre-infusion value)
(1 month post-treatment value - BL pre-infusion value)</description>
          <population>In the IV diphenhydramine arm 1 pt is missing HADS scores at 1 week, and 3 pts are missing scores at 1 month. In the IV Lidocaine arm 3 pts are missing HADS scores at 1 month.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anxiety 1 day change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-2" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-2" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety 1 week change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-2" upper_limit="-1"/>
                    <measurement group_id="O2" value="-2" lower_limit="-3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety 1 month change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-2.5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression 1 day change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-2.0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="-2" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression 1 week change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-2" upper_limit="-1"/>
                    <measurement group_id="O2" value="-2" lower_limit="-3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression 1 month change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-2" upper_limit="0"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-3" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IV Lidocaine</title>
          <description>IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes</description>
        </group>
        <group group_id="E2">
          <title>IV Diphenhydramine</title>
          <description>IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes</description>
        </group>
        <group group_id="E3">
          <title>Washout Period After IV Lidocaine</title>
          <description>Washout period after IV Lidocaine before IV diphenhydramine</description>
        </group>
        <group group_id="E4">
          <title>Washout Period After IV Diphenhydramine</title>
          <description>Washout period after IV diphenhydramine before IV Lidocaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Antje M Barreveld</name_or_title>
      <organization>Brigham &amp; Women's Hospital</organization>
      <phone>617-243-6298</phone>
      <email>abarreveld@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

